Growth differentiation factor 15: A biomarker to guide empagliflozin treatment in acute myocardial infarction?
Abstract
INTRODUCTION
Growth Differentiation Factor-15 (GDF-15) has been proven useful as a prognostic biomarker after an acute myocardial infarction (MI) and might be used to refine the selection of high-risk patients that could benefit from empagliflozin therapy. This study aims to compare the prognostic performance of GDF-15 with the inclusion criteria of the EMPACT-MI trial to identify patients at high risk of developing heart failure (HF) after an acute MI.
METHODS AND RESULTS
A cohort of 275 acute MI patients with GDF-15 concentration available and long-term follow-up was analyzed. Patients were classified into two categories, high risk (HRHF) or no high risk of development of HF (NHRHF), according to two models: 1) GDF-15: HRHF if >1800 ng/L and NHRHF if ≤1800 ng/L; and 2) EMPACT-MI criteria: HRHF if meeting the trial inclusion criteria. Cox regression and ROC curve analyses were used to evaluate the prognostic performance of both models. GDF-15 showed a stronger association with the composite endpoint of all-cause death or first hospitalization for HF (HR 10.7, 95 % CI 5.5-21.0) compared to EMPACT-MI inclusion criteria (HR 3.9, 95 % CI 2.2-6.8). Additionally, GDF-15 had superior discriminative ability (c-index 0.790 vs 0.629, p = 0.004). Similar results were obtained for HF first hospitalization.
CONCLUSIONS
GDF-15 may have a better discriminative ability than the inclusion criteria of the EMPACT-MI trial to identify those patients at higher risk of death and HF after an…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 275 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.